Indivior Pharmaceuticals announced a $175 million accelerated share repurchase agreement with Barclays as part of its existing $400 million buyback program. The company made an upfront payment and will receive an initial delivery of over 3.7 million shares, with final shares repurchased based on stock price through June 2026. This move reflects Indivior's confidence in its long-term strategy and cash flow, and it does not affect the company's financial guidance. The remaining $100 million of the repurchase authorization may be used for future share buybacks depending on market conditions.
LKQ Corporation announced it will publish its financial results for the second quarter of 2026 on July 30. The company will host a conference call and webcast with senior management to discuss the results, providing investors an opportunity to hear i...
First Federal Savings Bank and the Independent Community Bankers of America (ICBA) have issued 10 financial safety tips to help travelers manage their money securely during the summer travel season. Key advice includes notifying banks of travel plans...
Vivani Medical's wholly owned subsidiary Cortigent will merge with Nasdaq-listed ClearOne, which will be renamed Cortigent Holdings and trade under the ticker CRGT. Vivani will own a majority stake in the combined company, which will focus on advanci...
YD Bio Limited's U.S. affiliate, EG BioMed US, has secured clinical lab licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified, CAP-accredited lab's footprint to 46 states plus D.C. and Guam. This expansion enhances patient access to...
Diffusion, a global communications agency, is growing its home and interiors portfolio by signing new clients including POVISON (furniture), LUSA Lighting, and Induction Hardware (appliances). The agency will support these premium brands with integra...
